Skip to main content
. 2022 Dec 12;26(1):105799. doi: 10.1016/j.isci.2022.105799

Figure 6.

Figure 6

CTD multigene biomarkers are predictive of qualitative response and are also predictive of the best therapy for each PDX

(A) ROC for carboplatin complete response (CR) versus all else. The ROC for the CTD genes is in red, the ROC for WGCNA hub genes is in green, and the ROC for the WGCNA modules is in blue.

(B) ROC for carboplatin complete and partial response (CR/PR) versus all else. The ROC for the CTD genes is in red, the ROC for WGCNA hub genes is in green, and the ROC for the WGCNA modules is in blue.

(C) ROC for docetaxel complete response (CR) versus all else. The ROC for the CTD genes is in red, the ROC for WGCNA hub genes is in green, and the ROC for the WGCNA modules is in blue.

(D) ROC for docetaxel complete and partial response (CR/PR) versus all else. The ROC for the CTD genes is in red, the ROC for WGCNA hub genes is in green, and the ROC for the WGCNA modules is in blue.

(E) The best response predictions for all PDXs. If both the actual best therapy and the predicted best therapy is carboplatin, the dot is blue. If both the actual best therapy and the predicted best therapy is docetaxel, the dot is red. If the best therapy and the predicted best therapy do not match, the dot is black.

(F) The best response predictions for PDXs that are predicted to have a log2 fold-change difference of at least 2 between their response to carboplatin and their response to platinum. If both the actual best therapy and the predicted best therapy is carboplatin, the dot is blue. If both the actual best therapy and the predicted best therapy is docetaxel, the dot is red. If the best therapy and the predicted best therapy do not match, the dot is black.